NCT06377722 - Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions

Renal Cell Carcinoma MetastaticRenal Cell Carcinoma Stage IVRenal Cell Carcinoma Stage III

Interventions

DRUG

Cabozantinib

This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.

Trial Locations (8)

28041

Hospital Univeristario 12 de Octubre, Madrid

Unknown

Institut Català d'Oncologia. Idibell, L'Hospitalet de Llobregat

Hospital Universitario de Valdecilla, Santander

Hospital Universitario Central de Asturias, Oviedo

Centro Oncológico Clara Campal - HM CIOCC, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitario Severo Ochoa, Madrid